| Basics |
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders.
|
| IPO Date: |
October 5, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.77B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.75 | 2.97%
|
| Avg Daily Range (30 D): |
$1.35 | 2.19%
|
| Avg Daily Range (90 D): |
$1.30 | 2.31%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.4M |
| Avg Daily Volume (30 D): |
.49M |
| Avg Daily Volume (90 D): |
.52M |
| Trade Size |
| Avg Trade Size (Sh.): |
73 |
| Avg Trade Size (Sh.) (30 D): |
44 |
| Avg Trade Size (Sh.) (90 D): |
47 |
| Institutional Trades |
| Total Inst.Trades: |
2,424 |
| Avg Inst. Trade: |
$2.22M |
| Avg Inst. Trade (30 D): |
$3.4M |
| Avg Inst. Trade (90 D): |
$2.74M |
| Avg Inst. Trade Volume: |
.07M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3M |
| Avg Closing Trade (30 D): |
$5.09M |
| Avg Closing Trade (90 D): |
$4.55M |
| Avg Closing Volume: |
101.19K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-.81
|
$-.72
|
$-4.34
|
|
Diluted EPS
|
$-.81
|
$-.72
|
$-4.34
|
|
Revenue
|
$ 32.7M
|
$ 41.83M
|
$ 130.13M
|
|
Gross Profit
|
$ 29.06M
|
$ 38.04M
|
$ 116.76M
|
|
Net Income / Loss
|
$ -49.5M
|
$ -43.29M
|
$ -260.6M
|
|
Operating Income / Loss
|
$ -47M
|
$ -41.26M
|
$ -265.5M
|
|
Cost of Revenue
|
$ 3.65M
|
$ 3.79M
|
$ 13.37M
|
|
Net Cash Flow
|
$ 16.96M
|
$ 40.64M
|
$ 29.19M
|
|
PE Ratio
|
|
|
|
|
